Infectious Disease In-vitro Diagnostics Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
Description
Persistence Market Research has recently released a comprehensive report on the worldwide market for infectious disease in-vitro diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global infectious disease in-vitro diagnostics market from 2025 to 2032.
Key Insights:
Infectious disease in-vitro diagnostics (IVDs) play a crucial role in the detection, monitoring, and management of a broad range of infectious pathogens, including viruses, bacteria, fungi, and parasites. These diagnostics employ various technologies, such as molecular diagnostics, immunoassays, and microbiology techniques, to deliver accurate and timely results, aiding in effective clinical decision-making and infection control measures. The infectious disease IVD market caters to hospitals, diagnostic laboratories, research institutions, and point-of-care settings, offering a diverse portfolio of tests for diseases such as HIV, hepatitis, influenza, tuberculosis, COVID-19, and sexually transmitted infections. Market growth is driven by the increasing prevalence of infectious diseases, heightened focus on pandemic preparedness, and technological advancements enhancing test speed, sensitivity, and convenience.
Market Growth Drivers:
The global infectious disease IVD market is propelled by several key factors, including the rising global burden of infectious diseases and the growing demand for rapid, accurate diagnostic solutions to manage outbreaks and routine screening. The emergence and re-emergence of infectious pathogens, such as SARS-CoV-2, influenza variants, and antimicrobial-resistant bacteria, underscore the critical need for robust diagnostic tools. Technological innovations, including multiplex assays, high-throughput PCR platforms, and next-generation sequencing (NGS), are transforming infectious disease testing by enabling simultaneous detection of multiple pathogens with high precision. Moreover, increasing government investments in public health infrastructure, infectious disease surveillance, and pandemic response initiatives further stimulate market expansion. The rising adoption of point-of-care testing devices enhances access to diagnostics, especially in resource-limited settings, improving disease management and patient outcomes.
Market Restraints:
Despite strong growth prospects, the infectious disease IVD market faces challenges related to stringent regulatory approval processes, variability in diagnostic reimbursement policies, and the high cost of advanced molecular testing platforms. Regulatory requirements for demonstrating clinical performance, analytical validity, and safety can prolong product development timelines and increase compliance costs for manufacturers. Limited reimbursement coverage for certain molecular diagnostic tests, particularly in emerging economies, hampers market penetration and widespread adoption. Additionally, supply chain disruptions, as witnessed during the COVID-19 pandemic, pose risks to the timely availability of testing reagents and consumables. Addressing these challenges necessitates collaborative efforts among diagnostic companies, regulatory bodies, and healthcare stakeholders to streamline approval pathways and promote equitable access to reliable infectious disease diagnostics.
Market Opportunities:
The infectious disease IVD market presents significant growth opportunities driven by technological innovations, evolving healthcare delivery models, and rising global health awareness. Integration of digital health solutions, such as connected diagnostics and data analytics platforms, enhances disease surveillance, outbreak tracking, and personalized patient management. The expansion of molecular diagnostics beyond traditional infectious diseases to include antimicrobial resistance profiling and syndromic testing broadens the market scope and fosters innovation. Strategic collaborations, investments in R&D for novel biomarkers, and the development of affordable, user-friendly testing solutions tailored for decentralized and low-resource environments are essential to capitalize on emerging opportunities and maintain market leadership in the dynamic infectious disease diagnostics landscape.
Key Questions Answered in the Report:
These companies invest in R&D to develop high-sensitivity molecular assays, multiplexed platforms, and rapid point-of-care diagnostics, addressing diverse infectious disease testing needs. Partnerships with healthcare providers, governments, and international health organizations facilitate access to markets, especially during public health emergencies. Moreover, emphasis on automation, integration of digital solutions, and adherence to regulatory standards enables market leaders to deliver reliable, scalable, and cost-effective diagnostic solutions. Continuous efforts in clinical research, assay validation, and global distribution networks further consolidate the competitive landscape in the rapidly evolving infectious disease IVD market.
Key Companies Profiled:
The infectious disease IVD market encompasses a diverse range of products, technologies, applications, and end-user segments, addressing various pathogens and patient populations.
By Product Type
Please Note: It will take 5 business days to complete the report upon order confirmation.
Key Insights:
- Infectious Disease IVD Market Size (2025E): USD 46.6 Billion
- Projected Market Value (2032F): USD 64.1 Billion
- Global Market Growth Rate (CAGR 2025 to 2032): 4.7%
Infectious disease in-vitro diagnostics (IVDs) play a crucial role in the detection, monitoring, and management of a broad range of infectious pathogens, including viruses, bacteria, fungi, and parasites. These diagnostics employ various technologies, such as molecular diagnostics, immunoassays, and microbiology techniques, to deliver accurate and timely results, aiding in effective clinical decision-making and infection control measures. The infectious disease IVD market caters to hospitals, diagnostic laboratories, research institutions, and point-of-care settings, offering a diverse portfolio of tests for diseases such as HIV, hepatitis, influenza, tuberculosis, COVID-19, and sexually transmitted infections. Market growth is driven by the increasing prevalence of infectious diseases, heightened focus on pandemic preparedness, and technological advancements enhancing test speed, sensitivity, and convenience.
Market Growth Drivers:
The global infectious disease IVD market is propelled by several key factors, including the rising global burden of infectious diseases and the growing demand for rapid, accurate diagnostic solutions to manage outbreaks and routine screening. The emergence and re-emergence of infectious pathogens, such as SARS-CoV-2, influenza variants, and antimicrobial-resistant bacteria, underscore the critical need for robust diagnostic tools. Technological innovations, including multiplex assays, high-throughput PCR platforms, and next-generation sequencing (NGS), are transforming infectious disease testing by enabling simultaneous detection of multiple pathogens with high precision. Moreover, increasing government investments in public health infrastructure, infectious disease surveillance, and pandemic response initiatives further stimulate market expansion. The rising adoption of point-of-care testing devices enhances access to diagnostics, especially in resource-limited settings, improving disease management and patient outcomes.
Market Restraints:
Despite strong growth prospects, the infectious disease IVD market faces challenges related to stringent regulatory approval processes, variability in diagnostic reimbursement policies, and the high cost of advanced molecular testing platforms. Regulatory requirements for demonstrating clinical performance, analytical validity, and safety can prolong product development timelines and increase compliance costs for manufacturers. Limited reimbursement coverage for certain molecular diagnostic tests, particularly in emerging economies, hampers market penetration and widespread adoption. Additionally, supply chain disruptions, as witnessed during the COVID-19 pandemic, pose risks to the timely availability of testing reagents and consumables. Addressing these challenges necessitates collaborative efforts among diagnostic companies, regulatory bodies, and healthcare stakeholders to streamline approval pathways and promote equitable access to reliable infectious disease diagnostics.
Market Opportunities:
The infectious disease IVD market presents significant growth opportunities driven by technological innovations, evolving healthcare delivery models, and rising global health awareness. Integration of digital health solutions, such as connected diagnostics and data analytics platforms, enhances disease surveillance, outbreak tracking, and personalized patient management. The expansion of molecular diagnostics beyond traditional infectious diseases to include antimicrobial resistance profiling and syndromic testing broadens the market scope and fosters innovation. Strategic collaborations, investments in R&D for novel biomarkers, and the development of affordable, user-friendly testing solutions tailored for decentralized and low-resource environments are essential to capitalize on emerging opportunities and maintain market leadership in the dynamic infectious disease diagnostics landscape.
Key Questions Answered in the Report:
- What are the primary factors driving the growth of the infectious disease IVD market globally?
- Which test types and applications are driving the adoption of infectious disease diagnostics across various healthcare settings?
- How are technological advancements reshaping the competitive landscape of the infectious disease IVD market?
- Who are the key players contributing to the infectious disease IVD market, and what strategies are they employing to maintain market relevance?
- What are the emerging trends and future prospects in the global infectious disease IVD market?
These companies invest in R&D to develop high-sensitivity molecular assays, multiplexed platforms, and rapid point-of-care diagnostics, addressing diverse infectious disease testing needs. Partnerships with healthcare providers, governments, and international health organizations facilitate access to markets, especially during public health emergencies. Moreover, emphasis on automation, integration of digital solutions, and adherence to regulatory standards enables market leaders to deliver reliable, scalable, and cost-effective diagnostic solutions. Continuous efforts in clinical research, assay validation, and global distribution networks further consolidate the competitive landscape in the rapidly evolving infectious disease IVD market.
Key Companies Profiled:
- QIAGEN
- Becton, Dickinson and Company
- bioMérieux SA
- F. Hoffmann-La Roche, Ltd.
- Hologic, Inc. (Gen Probe)
- Abbott
- Quidel Corporation
- Siemens Healthineers AG
- Bio-Rad Laboratories, Inc.
- Danaher
- OraSure Technologies, Inc.
The infectious disease IVD market encompasses a diverse range of products, technologies, applications, and end-user segments, addressing various pathogens and patient populations.
By Product Type
- Instruments
- Reagents
- Software and Services
- Immunoassay
- Molecular Diagnostics
- Microbiology
- Others
- MRSA
- Clostridium Difficile
- Respiratory Virus
- TB and Drug-resistant TB
- Gonorrhea
- HPV
- HIV
- Hepatitis C
- Hepatitis B
- COVID-19
- Others
- Point-of-care
- Central Laboratories
- Others
- North America
- Europe
- East Asia
- South Asia and Oceania
- Latin America
- Middle East and Africa
Please Note: It will take 5 business days to complete the report upon order confirmation.
Table of Contents
188 Pages
- 1. Executive Summary
- 1.1. Global Infectious Disease In-vitro Diagnostics Market Snapshot, 2025 and 2032
- 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
- 2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.4. COVID-19 Impact Analysis
- 2.5. Forecast Factors – Relevance and Impact
- 3. Value Added Insights
- 3.1. Regulatory Landscape
- 3.2. Product Adoption Analysis
- 3.3. Value Chain Analysis
- 3.4. Key Deals and Mergers
- 3.5. PESTLE Analysis
- 3.6. Porter’s Five Force Analysis
- 4. Global Infectious Disease In-vitro Diagnostics Market Outlook:
- 4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
- 4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025–2032
- 4.3. Global Infectious Disease In-vitro Diagnostics Market Outlook: Product Type
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019-2024
- 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 4.3.3.1. Instruments
- 4.3.3.2. Reagents
- 4.3.3.3. Software and Services
- 4.3.4. Market Attractiveness Analysis: Product Type
- 4.4. Global Infectious Disease In-vitro Diagnostics Market Outlook: Technology
- 4.4.1. Introduction / Key Findings
- 4.4.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2024
- 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 4.4.3.1. Immunoassay
- 4.4.3.2. Molecular Diagnostics
- 4.4.3.3. Microbiology
- 4.4.3.4. Others
- 4.4.4. Market Attractiveness Analysis: Technology
- 4.5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Application
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
- 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 4.5.3.1. MRSA
- 4.5.3.2. Clostridium Difficile
- 4.5.3.3. Respiratory Virus
- 4.5.3.4. TB and Drug-resistant TB
- 4.5.3.5. Gonorrhea
- 4.5.3.6. HPV
- 4.5.3.7. HIV
- 4.5.3.8. Hepatitis C
- 4.5.3.9. Hepatitis B
- 4.5.3.10. COVID-19
- 4.5.3.11. Others
- 4.5.4. Market Attractiveness Analysis: Application
- 4.6. Global Infectious Disease In-vitro Diagnostics Market Outlook: End User
- 4.6.1. Introduction / Key Findings
- 4.6.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2024
- 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 4.6.3.1. Point-of-care
- 4.6.3.2. Central Laboratories
- 4.6.3.3. Others
- 4.6.4. Market Attractiveness Analysis: End User
- 5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Region
- 5.1. Key Highlights
- 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
- 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
- 5.4. Market Attractiveness Analysis: Region
- 6. North America Infectious Disease In-vitro Diagnostics Market Outlook:
- 6.1. Key Highlights
- 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 6.2.1. By Country
- 6.2.2. By Product Type
- 6.2.3. By Technology
- 6.2.4. By Application
- 6.2.5. By End User
- 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 6.3.1. U.S.
- 6.3.2. Canada
- 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 6.4.1. Instruments
- 6.4.2. Reagents
- 6.4.3. Software and Services
- 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 6.5.1. Immunoassay
- 6.5.2. Molecular Diagnostics
- 6.5.3. Microbiology
- 6.5.4. Others
- 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 6.6.1. MRSA
- 6.6.2. Clostridium Difficile
- 6.6.3. Respiratory Virus
- 6.6.4. TB and Drug-resistant TB
- 6.6.5. Gonorrhea
- 6.6.6. HPV
- 6.6.7. HIV
- 6.6.8. Hepatitis C
- 6.6.9. Hepatitis B
- 6.6.10. COVID-19
- 6.6.11. Others
- 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 6.7.1. Point-of-care
- 6.7.2. Central Laboratories
- 6.7.3. Others
- 6.8. Market Attractiveness Analysis
- 7. Europe Infectious Disease In-vitro Diagnostics Market Outlook:
- 7.1. Key Highlights
- 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 7.2.1. By Country
- 7.2.2. By Product Type
- 7.2.3. By Technology
- 7.2.4. By Application
- 7.2.5. By End User
- 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Russia
- 7.3.7. Rest of Europe
- 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 7.4.1. Instruments
- 7.4.2. Reagents
- 7.4.3. Software and Services
- 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 7.5.1. Immunoassay
- 7.5.2. Molecular Diagnostics
- 7.5.3. Microbiology
- 7.5.4. Others
- 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 7.6.1. MRSA
- 7.6.2. Clostridium Difficile
- 7.6.3. Respiratory Virus
- 7.6.4. TB and Drug-resistant TB
- 7.6.5. Gonorrhea
- 7.6.6. HPV
- 7.6.7. HIV
- 7.6.8. Hepatitis C
- 7.6.9. Hepatitis B
- 7.6.10. COVID-19
- 7.6.11. Others
- 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 7.7.1. Point-of-care
- 7.7.2. Central Laboratories
- 7.7.3. Others
- 7.8. Market Attractiveness Analysis
- 8. East Asia Infectious Disease In-vitro Diagnostics Market Outlook:
- 8.1. Key Highlights
- 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 8.2.1. By Country
- 8.2.2. By Product Type
- 8.2.3. By Technology
- 8.2.4. By Application
- 8.2.5. By End User
- 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 8.4.1. Instruments
- 8.4.2. Reagents
- 8.4.3. Software and Services
- 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 8.5.1. Immunoassay
- 8.5.2. Molecular Diagnostics
- 8.5.3. Microbiology
- 8.5.4. Others
- 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 8.6.1. MRSA
- 8.6.2. Clostridium Difficile
- 8.6.3. Respiratory Virus
- 8.6.4. TB and Drug-resistant TB
- 8.6.5. Gonorrhea
- 8.6.6. HPV
- 8.6.7. HIV
- 8.6.8. Hepatitis C
- 8.6.9. Hepatitis B
- 8.6.10. COVID-19
- 8.6.11. Others
- 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 8.7.1. Point-of-care
- 8.7.2. Central Laboratories
- 8.7.3. Others
- 8.8. Market Attractiveness Analysis
- 9. South Asia & Oceania Infectious Disease In-vitro Diagnostics Market Outlook:
- 9.1. Key Highlights
- 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 9.2.1. By Country
- 9.2.2. By Product Type
- 9.2.3. By Technology
- 9.2.4. By Application
- 9.2.5. By End User
- 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 9.3.1. India
- 9.3.2. Southeast Asia
- 9.3.3. ANZ
- 9.3.4. Rest of South Asia & Oceania
- 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 9.4.1. Instruments
- 9.4.2. Reagents
- 9.4.3. Software and Services
- 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 9.5.1. Immunoassay
- 9.5.2. Molecular Diagnostics
- 9.5.3. Microbiology
- 9.5.4. Others
- 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 9.6.1. MRSA
- 9.6.2. Clostridium Difficile
- 9.6.3. Respiratory Virus
- 9.6.4. TB and Drug-resistant TB
- 9.6.5. Gonorrhea
- 9.6.6. HPV
- 9.6.7. HIV
- 9.6.8. Hepatitis C
- 9.6.9. Hepatitis B
- 9.6.10. COVID-19
- 9.6.11. Others
- 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 9.7.1. Point-of-care
- 9.7.2. Central Laboratories
- 9.7.3. Others
- 9.8. Market Attractiveness Analysis
- 10. Latin America Infectious Disease In-vitro Diagnostics Market Outlook:
- 10.1. Key Highlights
- 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 10.2.1. By Country
- 10.2.2. By Product Type
- 10.2.3. By Technology
- 10.2.4. By Application
- 10.2.5. By End User
- 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 10.3.1. Brazil
- 10.3.2. Mexico
- 10.3.3. Rest of Latin America
- 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 10.4.1. Instruments
- 10.4.2. Reagents
- 10.4.3. Software and Services
- 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 10.5.1. Immunoassay
- 10.5.2. Molecular Diagnostics
- 10.5.3. Microbiology
- 10.5.4. Others
- 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 10.6.1. MRSA
- 10.6.2. Clostridium Difficile
- 10.6.3. Respiratory Virus
- 10.6.4. TB and Drug-resistant TB
- 10.6.5. Gonorrhea
- 10.6.6. HPV
- 10.6.7. HIV
- 10.6.8. Hepatitis C
- 10.6.9. Hepatitis B
- 10.6.10. COVID-19
- 10.6.11. Others
- 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 10.7.1. Point-of-care
- 10.7.2. Central Laboratories
- 10.7.3. Others
- 10.8. Market Attractiveness Analysis
- 11. Middle East & Africa Infectious Disease In-vitro Diagnostics Market Outlook:
- 11.1. Key Highlights
- 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 11.2.1. By Country
- 11.2.2. By Product Type
- 11.2.3. By Technology
- 11.2.4. By Application
- 11.2.5. By End User
- 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 11.3.1. GCC Countries
- 11.3.2. Egypt
- 11.3.3. South Africa
- 11.3.4. Northern Africa
- 11.3.5. Rest of Middle East & Africa
- 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 11.4.1. Instruments
- 11.4.2. Reagents
- 11.4.3. Software and Services
- 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 11.5.1. Immunoassay
- 11.5.2. Molecular Diagnostics
- 11.5.3. Microbiology
- 11.5.4. Others
- 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 11.6.1. MRSA
- 11.6.2. Clostridium Difficile
- 11.6.3. Respiratory Virus
- 11.6.4. TB and Drug-resistant TB
- 11.6.5. Gonorrhea
- 11.6.6. HPV
- 11.6.7. HIV
- 11.6.8. Hepatitis C
- 11.6.9. Hepatitis B
- 11.6.10. COVID-19
- 11.6.11. Others
- 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 11.7.1. Point-of-care
- 11.7.2. Central Laboratories
- 11.7.3. Others
- 11.8. Market Attractiveness Analysis
- 12. Competition Landscape
- 12.1. Market Share Analysis, 2025
- 12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
- 12.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
- 12.3.1. QIAGEN
- 12.3.1.1. Overview
- 12.3.1.2. Segments and Products
- 12.3.1.3. Key Financials
- 12.3.1.4. Market Developments
- 12.3.1.5. Market Strategy
- 12.3.2. Becton, Dickinson and Company
- 12.3.3. bioMérieux SA
- 12.3.4. F. Hoffmann-La Roche, Ltd.
- 12.3.5. Hologic, Inc. (Gen Probe)
- 12.3.6. Abbott
- 12.3.7. Quidel Corporation
- 12.3.8. Siemens Healthineers AG
- 12.3.9. Bio-Rad Laboratories, Inc.
- 12.3.10. Danaher
- 12.3.11. OraSure Technologies, Inc.
- 12.3.12. Others
- 13. Appendix
- 13.1. Research Methodology
- 13.2. Research Assumptions
- 13.3. Acronyms and Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
